UA84047U - Method for treatment of secondary disordes of hemostasis system in patients with hemophilia with large intra-muscle hematomas - Google Patents

Method for treatment of secondary disordes of hemostasis system in patients with hemophilia with large intra-muscle hematomas

Info

Publication number
UA84047U
UA84047U UAU201304167U UAU201304167U UA84047U UA 84047 U UA84047 U UA 84047U UA U201304167 U UAU201304167 U UA U201304167U UA U201304167 U UAU201304167 U UA U201304167U UA 84047 U UA84047 U UA 84047U
Authority
UA
Ukraine
Prior art keywords
hematomas
hemophilia
muscle
patients
disordes
Prior art date
Application number
UAU201304167U
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Анатолий Владимирович Стариков
Петр Васильевич Ющенко
Александр Валерьевич Асса
Владимир Иванович Семеняка
Милитина Юрьевна Аношина
Светлана Валентиновна Бурнаева
Евгений Валентинович Аверьянов
Лилия Валерьевна Баронская
Original Assignee
Государственное Учреждение "Институт Гематологии И Трансфузиологии Намн Украины"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Государственное Учреждение "Институт Гематологии И Трансфузиологии Намн Украины" filed Critical Государственное Учреждение "Институт Гематологии И Трансфузиологии Намн Украины"
Priority to UAU201304167U priority Critical patent/UA84047U/en
Publication of UA84047U publication Critical patent/UA84047U/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method for treating secondary hemostatic disorders in patients with hemophilia with large intra-muscle hematomas by substituted transfusion therapy. Additionally, the infusion is carried out with 4% solution of succinylated gelatin of dosage 5.7 ml/kg of body weight per day and enterosorbent silicon dioxide is used orally at a dose of 4 g three times a day for 10 days.
UAU201304167U 2013-04-03 2013-04-03 Method for treatment of secondary disordes of hemostasis system in patients with hemophilia with large intra-muscle hematomas UA84047U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201304167U UA84047U (en) 2013-04-03 2013-04-03 Method for treatment of secondary disordes of hemostasis system in patients with hemophilia with large intra-muscle hematomas

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201304167U UA84047U (en) 2013-04-03 2013-04-03 Method for treatment of secondary disordes of hemostasis system in patients with hemophilia with large intra-muscle hematomas

Publications (1)

Publication Number Publication Date
UA84047U true UA84047U (en) 2013-10-10

Family

ID=52283404

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201304167U UA84047U (en) 2013-04-03 2013-04-03 Method for treatment of secondary disordes of hemostasis system in patients with hemophilia with large intra-muscle hematomas

Country Status (1)

Country Link
UA (1) UA84047U (en)

Similar Documents

Publication Publication Date Title
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MX2022003072A (en) Use of pridopidine for treating functional decline.
PH12016500433A1 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2021002321A (en) Novel methods.
BR112017006272A2 (en) The medicine constituent for medical treatment of chronic ulcerative colitis
EA201691656A2 (en) THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
MX2016008027A (en) Use of laquinimod to delay huntington's disease progression.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2019006942A (en) Non-peptide oxytocin receptor agonists.
MX2018011607A (en) Sultiame for the treatment of sleep apnea.
UA84047U (en) Method for treatment of secondary disordes of hemostasis system in patients with hemophilia with large intra-muscle hematomas
MX2018005876A (en) Plasminogen dosage regimen for wound healing.
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
RU2012115039A (en) METHOD FOR TREATING CHRONIC ENDOMETRITIS
SG11201809042SA (en) Inhaled preparation of isoglycyrrhizic acid or salt thereof, and use in preparing drugs for treating respiratory system diseases
UA96488U (en) A method for treating disorders of hemovascular hemostasis in patients with ischemic heart disease
UA115063U (en) METHOD OF TREATMENT OF DOGS WITH PAIN SYNDROME IN PANCREATITIS
MDS20160124U2 (en) Method for prophylaxis of prolonged lymphorrhagia in the radical treatment of breast cancer in patients with type 2 diabetes
RU2012149676A (en) METHOD FOR TREATING CALVES WITH PATIENTS WITH SIMULIIDOTOXICOSIS
UA95104U (en) METHOD OF THERAPY OF PATIENTS WITH NON-HOSPITAL PNEUMONIA WITH COMPLETE CHF
UA89024U (en) Method for complex treatment of ureterolithiasis
AR102903A1 (en) DRY POWDER INHALER